Pharmacology News

Health care costs remained high for Medicare beneficiaries with common chronic conditions for which brand-name medications without generic alternatives were recommended, according to findings published in JAMA Internal Medicine.

Although COVID-19 remained a popular topic among Healio Primary Care readers in 2021, other stories that discussed diabetes screening and physician suicide also generated significant attention.

As of Dec. 1, the FDA had approved 46 novel drugs this year, one fewer than it had approved by the same date in 2020.

Novartis announced the FDA approved inclisiran, its small-interfering RNA therapy for LDL lowering.

Healio’s coverage of sleep studies throughout the year highlight the importance of a good night’s rest.

Anticoagulation with rivaroxaban for patients with atrial fibrillation aged 65 years or more was associated with greater risk for major ischemic and hemorrhagic events compared with apixaban, according to data published in JAMA.

The monoclonal antibody bamlanivimab may be effective in treating hospitalized patients with SARS-CoV-2 infection if they have no detectable levels of endogenous neutralizing antibodies prior to administration, according to researchers.

Aspirin use for primary atherosclerotic CVD prevention continues to be prevalent in adults aged 70 years or older despite contrary guideline recommendations, according to data published in the American Journal of Preventive Cardiology.

The evidence base is growing for a psychoactive substance in the treatment of PTSD, according to the co-author of a systematic review and meta-analysis exploring the therapy’s potential.

FDA recently approved Lybalvi for the treatment of schizophrenia and for use in manic and mixed (depressive and manic) episodes of bipolar I disorder as an acute treatment, a maintenance treatment, and for use with valproate or lithium.